ABVX:EPA
Abivax SA
84,80 €
arrow_upward
+1,86%(+1,55) 1D
21-окт., 17:27:54 GMT+2 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ABVX...
Open
83,25 €
High
85,80 €
Low
82,25 €
Mkt. cap
7,35 млд
Avg. vol.
121,63 миң
Volume
42,97 миң
52-wk high
139,00 €
52-wk low
60,45 €
EPS
-5,20 €
Shares outstanding
87,55 млн
No. of employees
98
Open
83,25 €
High
85,80 €
Low
82,25 €
Mkt. cap
7,35 млд
Avg. vol.
121,63 миң
Volume
42,97 миң
52-wk high
139,00 €
52-wk low
60,45 €
EPS
-5,20 €
Shares outstanding
87,55 млн
No. of employees
98
News stories
From web sources and news partners
MarketBeat
·
14 мүнөт мурун
Amplitude (NASDAQ:AMPL) Reaches New 12-Month High Following Analyst Upgrade
GuruFocus
·
6 мүнөт мурун
Dow (DOW) Prepares to Report Q3 Earnings Amid Mixed Guidance and Market Optimism
Seeking Alpha
·
56 мүнөт мурун
S&P 500 Sector Rotation Tracker: Energy takes the wheel as tech hits the brakes (SPY:NYSEARCA)
Reuters
·
1 саат мурун
Nasdaq leads gains as SpaceX, Super Micro results improve AI appetite
Profile
Abivax SA is a clinical stage biotechnology company focused on developing innovative treatments that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases.
Abivax has a program in clinical development with its lead drug candidate, obefazimod, to treat ulcerative colitis. Another program in Crohn’s disease is also in preparation and other potential inflammatory indications are being evaluated.
The company’s headquarters are based in Paris, France with a US office in Waltham, Massachusetts. Abivax’s Research and development work is conducted at its research center based in Montpellier, France. Wikipedia
About Abivax SA
CEOMarc de Garidel | Hartmut J. Ehrlich
Employees98
Founded2013-ж., 4-дек.
Headquarters-
Sector-
Websiteabivax.com